Clinical Trial Update: A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety, tolerability, and efficacy of a two-course Itacitinib regimen in adults with active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED